Understanding and overcoming resistance to immunotherapy in genitourinary cancers

Understanding and overcoming resistance to immunotherapy in genitourinary cancers

The introduction of novel immunotherapies has significantly transformed the treatment landscape of genitourinary (GU) cancers, even becoming the standard of care in some settings. One such type of immunotherapy, immune checkpoint inhibitors (ICIs) like nivolumab, ipilimumab, pembrolizumab, and atezo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sean T Evans, Yash Jani, Caroline S Jansen, Ahmet Yildirim, Ecem Kalemoglu, Mehmet Asim Bilen
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Cancer Biology & Therapy
Subjects:	Nivolumab ipilimumab programmed cell death protein-1 (PD-1) programmed death ligand-1 (PD-L1) immune checkpoint inhibitors immunotherapy resistance
Online Access:	https://www.tandfonline.com/doi/10.1080/15384047.2024.2342599
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers
by: Ecem Kalemoglu, et al.
Published: (2025-04-01)

Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck
by: Yu. V. Kostalanova, et al.
Published: (2020-11-01)

Real-world data on immune checkpoint inhibitors in advanced sarcomas across multiple European institutions
by: Stefania Kokkali, et al.
Published: (2025-06-01)

Clinicopathologic and prognosis of 30 patients with FH-deficient renal cell carcinoma: a single-center retrospective study
by: Junjie Bai, et al.
Published: (2025-07-01)

Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study
by: Alessandro Inno, et al.
Published: (2025-07-01)

Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors combined with chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis
by: Jiaojiao Yu, et al.
Published: (2025-05-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01)

Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors
by: Seher Şener, et al.
Published: (2021-10-01)

Development and Validation of a Biolayer Interferometry Method for Determination of Human Anti-PD-1 Monoclonal Antibody Concentration in Cynomolgus Serum
by: K. V. Ulyanova, et al.
Published: (2020-12-01)

Case Report: Long-term response control in a patient with metastatic gastric squamous cell carcinoma treated with nivolumab and chemoradiotherapy
by: Yu-ying Lei, et al.
Published: (2025-08-01)

Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
by: Hanan R. Nada, et al.
Published: (2025-01-01)

Dramatic Metabolic Response to Dual ICI With Chemotherapy in Low PD‐L1 NSCLC Case
by: Toshikazu Kumasa, et al.
Published: (2025-03-01)

Pembrolizumab associated hypereosinophilia in locally advanced triple-negative breast cancer
by: Remo Poto, et al.
Published: (2025-03-01)

Pembrolizumab‐induced acquired perforating dermatosis
by: Yaron Gu, et al.
Published: (2024-12-01)

Predicting PD-L1 status in NSCLC patients using deep learning radiomics based on CT images
by: Jiameng Lu, et al.
Published: (2025-04-01)

PD-L1 on Circulating Tumor Cells Indicates Poor Prognosis in Breast Cancer
by: Xue-fei Wang, et al.
Published: (2022-11-01)

Influence of programmed death ligand 1 (PD-L1) knockout on gut microbiota in experimental autoimmune uveitis
by: Junxiang Gu, et al.
Published: (2025-05-01)

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis
by: Tzu-Rong Peng, et al.
Published: (2023-11-01)

The features of PD-L1 expression in tumor stromal cells, peritumoral microvessels and isolated clusters of tumor cells in breast cancer tissue and their correlation with clinical and morphological characteristics of breast cancer
by: E. Yu. Zubareva, et al.
Published: (2023-11-01)

Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study
by: Anastasia Rays, et al.
Published: (2025-03-01)

PD-L1 deficiency exacerbates colitis severity by remodeling gut microbiota in inflammatory bowel disease
by: Yixian Ma, et al.
Published: (2025-06-01)

Accessing utility of immunohistochemistry, PD-L1 correlation with stage of cancer and EGFR mutation with disease survival in primary lung carcinoma
by: Kartavya Kumar Verma, et al.
Published: (2025-06-01)

Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring
by: Chunyan Liu, et al.
Published: (2023-04-01)

A novel deep learning framework for automatic scoring of PD-L1 expression in non-small cell lung cancer
by: Saidul Kabir, et al.
Published: (2025-03-01)

Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs
by: Naoya Maekawa, et al.
Published: (2025-05-01)

Nivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review
by: D. D. Ivanova, et al.
Published: (2024-12-01)

MODERN TREATMENT OF METASTATIC MELANOMA: FROM STANDARDS TO AN INDIVIDUALIZED APPROACH IN REAL CLINICAL PRACTICE
by: N. V. Zhukova, et al.
Published: (2018-06-01)

Usnea acid inhibits the proliferation of human ovarian cancer cell line
by: SHEN Hongmei, YU Yan, FENG Xuqiang, WANG Keqiang
Published: (2025-01-01)

Residue-Specific Epitope Mapping of the PD-1/Nivolumab Interaction Using X-ray Footprinting Mass Spectrometry
by: Line G. Kristensen, et al.
Published: (2024-09-01)

Detection of PD-L1 expression levels in malignant pleural mesothelioma with a targeted MRI nanoprobe in vivo
by: Zhenghua Zhang, et al.
Published: (2024-12-01)

Association of Hepatitis-B virus infection status with survival and treatment response in non-small cell lung cancer patients on anti‐pd‐1/pd-l1 therapy
by: Eda Alp, et al.
Published: (2024-12-01)

Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression
by: Wei-Wen Sung, et al.
Published: (2022-01-01)

T-cell invigoration to cell-free DNA ratio associated with anti-PD-1 response in gastric or gastro-esophageal junction adenocarcinoma: VOYAGER trial
by: A. Makiyama, et al.
Published: (2025-06-01)

CD4 T cells correlate with better prognosis in medulloblastoma
by: Jin Zhang, et al.
Published: (2025-06-01)

Evaluation of the diagnostic concordance of FDA-approved PD-L1 assays in clear cell renal cell carcinoma
by: Yoko Koh, et al.
Published: (2025-07-01)

Isolated tumor cell clusters (ITC) in lymph nodes and PD-L1 expression on tumor-associated immune cells are prognostic factors for microsatellite instable-high gastric cancers
by: Menghan Cui, et al.
Published: (2025-09-01)

Enhanced potency of immune checkpoint inhibitors against poorly immunological solid tumors by immune stimulatory oncolytic adenoviruses-mediated remodeling of the tumor microenvironment
by: Hyo Min Ahn, et al.
Published: (2025-05-01)

Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study
by: Dmitry Shchelokov, et al.
Published: (2023-12-01)

An Fe(III)-covalent organic framework (COF)–sorafenib nanoplatform induces chemo-ferroptosis for enhanced hepatocellular carcinoma immunotherapy
by: Binglong Bai, et al.
Published: (2025-10-01)